American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision

被引:0
作者
Studenic, Paul [1 ,2 ]
Aletaha, Daniel [2 ]
de Wit, Maarten [3 ]
Stamm, Tanja A. [2 ]
Alasti, Farideh [2 ]
Lacaille, Diane [4 ,5 ]
Smolen, Josef S. [2 ]
Felson, David T. [6 ]
机构
[1] Karolinska Inst, Div Rheumatol, Dept Med Solna, Stockholm, Sweden
[2] Med Univ Vienna, Dept Internal Med 3, Div Rheumatol, Vienna, Austria
[3] EULAR Community People Arthrit Rheumatism Europe, Zurich, Switzerland
[4] Univ British Columbia, Dept Med, Div Rheumatol, Vancouver, BC, Canada
[5] Arthrit Res Canada, Vancouver, BC, Canada
[6] Boston Univ, Sch Med, Sect Rheumatol, Boston, MA 02118 USA
关键词
Arthritis; Rheumatoid; Methotrexate; PATIENT GLOBAL ASSESSMENT; DISEASE-ACTIVITY; RECOMMENDATIONS; METHOTREXATE; TRIAL; LEAGUE; DAMAGE; NAIVE; INDEX;
D O I
10.1136/ard-2022-223413
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent studies indicating that a higher threshold for the patient global assessment (PtGA) may improve agreement between the two sets of criteria, our goals were to externally validate a revision of the Boolean remission criteria using a higher PtGA threshold and to validate the provisionally endorsed index-based criteria. Methods We used data from four randomised trials comparing biological disease-modifying antirheumatic drugs to methotrexate or placebo. We tested the higher proposed PtGA threshold of 2 cm (Boolean2.0) (range 0-10 cm) compared with the original threshold of 1 cm (Boolean1.0). We analysed agreement between the Boolean-based and index-based criteria (Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI)) for remission and examined how well each remission definition predicted later good physical function (Health Assessment Questionnaire (HAQ) score <= 0.5) and radiographic non-progression. Results Data from 2048 trial participants, 1101 with early RA and 947 with established RA, were included. The proportion of patients with disease in remission at 6 months after treatment initiation increased when using Boolean2.0 compared with Boolean1.0, from 14.8% to 20.6% in early RA and 4.2% to 6.0% in established RA. Agreement between Boolean2.0 and the SDAI or CDAI remission criteria was better than for Boolean1.0, particularly in early disease. Boolean2.0, SDAI, and CDAI remission criteria had similar positive likelihood ratios (LRs) to predict radiographic nonprogression and a HAQ score of <= 0.5 (positive LR 3.8-4.3). The omission of PtGA (BooleanX) worsened the prediction of good functional outcomes. Conclusion Using the Boolean 2.0 criteria classifies, more patients as achieving remission and increases the agreement with index-based remission criteria without jeopardising predictive value for radiographic or functional outcomes. This revised Boolean definition and the previously provisionally endorsed index-based criteria were endorsed by ACR and EULAR.
引用
收藏
页码:74 / 80
页数:7
相关论文
共 41 条
[1]   Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials [J].
Aletaha, D ;
Ward, MM .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (02) :227-233
[2]   Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score [J].
Aletaha, D ;
Nell, VP ;
Stamm, T ;
Uffmann, M ;
Pflugbeil, S ;
Machold, K ;
Smolen, JS .
ARTHRITIS RESEARCH & THERAPY, 2005, 7 (04) :R796-R806
[3]   Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction [J].
Aletaha, Daniel ;
Funovits, Julia ;
Smolen, Josef S. .
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (05) :733-739
[4]   Patient global assessment to define remission in rheumatoid arthritis: quo vadis? [J].
Boers, Maarten .
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (03) :277-279
[5]   A COMPARISON OF HEALTH-RELATED QUALITY-OF-LIFE MEASURES FOR RHEUMATOID-ARTHRITIS RESEARCH [J].
BOMBARDIER, C ;
RABOUD, J .
CONTROLLED CLINICAL TRIALS, 1991, 12 (04) :S243-S256
[6]   Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial [J].
Burmester, Gerd R. ;
Rigby, William F. ;
van Vollenhoven, Ronald F. ;
Kay, Jonathan ;
Rubbert-Roth, Andrea ;
Blanco, Ricardo ;
Kadva, Alysha ;
Dimonaco, Sophie .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (07) :1279-1284
[7]   Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial [J].
Combe, Bernard ;
Kivitz, Alan ;
Tanaka, Yoshiya ;
van der Heijde, Desiree ;
Simon, J. Abraham ;
Baraf, Herbert S. B. ;
Kumar, Uma ;
Matzkies, Franziska ;
Bartok, Beatrix ;
Ye, Lei ;
Guo, Ying ;
Tasset, Chantal ;
Sundy, John S. ;
Jahreis, Angelika ;
Genovese, Mark C. ;
Mozaffarian, Neelufar ;
Landewe, Robert B. M. ;
Bae, Sang-Cheol ;
Keystone, Edward C. ;
Nash, Peter .
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (07) :848-858
[8]   Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)) [J].
Emery, P. ;
Deodhar, A. ;
Rigby, W. F. ;
Isaacs, J. D. ;
Combe, B. ;
Racewicz, A. J. ;
Latinis, K. ;
Abud-Mendoza, C. ;
Szczepanski, L. J. ;
Roschmann, R. A. ;
Chen, A. ;
Armstrong, G. K. ;
Douglass, W. ;
Tyrrell, H. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (09) :1629-1635
[9]   EARLY RHEUMATOID-ARTHRITIS - TIME TO AIM FOR REMISSION [J].
EMERY, P ;
SALMON, M .
ANNALS OF THE RHEUMATIC DISEASES, 1995, 54 (12) :944-947
[10]   American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials [J].
Felson, David T. ;
Smolen, Josef S. ;
Wells, George ;
Zhang, Bin ;
van Tuyl, Lilian H. D. ;
Funovits, Julia ;
Aletaha, Daniel ;
Allaart, Cornelia F. ;
Bathon, Joan ;
Bombardieri, Stefano ;
Brooks, Peter ;
Brown, Andrew ;
Matucci-Cerinic, Marco ;
Choi, Hyon ;
Combe, Bernard ;
de Wit, Maarten ;
Dougados, Maxime ;
Emery, Paul ;
Furst, Daniel ;
Gomez-Reino, Juan ;
Hawker, Gillian ;
Keystone, Edward ;
Khanna, Dinesh ;
Kirwan, John ;
Kvien, Tore K. ;
Landewe, Robert ;
Listing, Joachim ;
Michaud, Kaleb ;
Martin-Mola, Emilio ;
Montie, Pamela ;
Pincus, Theodore ;
Richards, Pamela ;
Siegel, Jeffrey N. ;
Simon, Lee S. ;
Sokka, Tuulikki ;
Strand, Vibeke ;
Tugwell, Peter ;
Tyndall, Alan ;
van der Heijde, Desiree ;
Verstappen, Suzan ;
White, Barbara ;
Wolfe, Frederick ;
Zink, Angela ;
Boers, Maarten .
ARTHRITIS AND RHEUMATISM, 2011, 63 (03) :573-586